MedPath

Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea

Phase 4
Terminated
Conditions
Obstructive Sleep Apnea
Delayed Emergence From Anesthesia
Interventions
Drug: Placebo
Drug: Modafinil
Registration Number
NCT02494102
Lead Sponsor
Milton S. Hershey Medical Center
Brief Summary

The purpose of this study is to determine whether modafinil use in patients with obstructive sleep apnea will improve postoperative delayed emergence after general anesthesia.

Detailed Description

This is a randomized, double blind placebo controlled evaluation of modafinil versus placebo for the treatment of general anesthesia related delayed emergence in patients with the diagnosis of obstructive sleep apnea. 124 patients will be recruited and randomized on the day of surgery to receive 200mg modafinil or placebo. After randomization, patients will proceed to the operative suite for surgical procedure under general anesthesia. The primary outcome measured will be post-anesthesia care unit length of stay. Secondary outcomes will include performance on a post-anesthesia recovery scale.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
105
Inclusion Criteria
  1. 18 years or older
  2. Meets diagnostic criteria for obstructive sleep apnea
  3. Willing and able to comply with study procedures
  4. Willing and able to provide informed consent
  5. If female, not pregnant or lactating and willing to use an acceptable method of barrier birth control (e.g. condoms) for one month after surgery and discontinuation of study medication (modafinil may reduce the effectiveness of steroidal contraception for one month after discontinuation)
Read More
Exclusion Criteria
  1. Have a medical condition that, in the study physician's judgment, may interfere with safe participation (active cardiac conditions such as angina, recent myocardial infarction w/in 6 months, severe renal or liver disease, unstable diabetes, or elevated liver enzymes greater than twice normal).
  2. Have a current neurological disorder (e.g. organic brain disease, dementia) or major psychiatric condition that would impair the collection of data (schizophrenia, bipolar illness).
  3. Currently on prescription medication that is known to interact with the study drug. (ethinylestradiol and triazolam).
  4. Have current dependence on cocaine, methamphetamine, alcohol or benzodiazepines (DSM-IV criteria).
  5. Have a history of severe valvular heart disease, severe left ventricular hypertrophy, cardiac arrhythmias, angina, cardiac syncope, or pre-syncope or myocardial infarction <6 months.
  6. Have a history of uncontrolled or poorly controlled essential hypertension, or a heart rate greater than 70% of the maximum heart rate expected for their age (Formula: 0.70(220 - age).
  7. Any condition, in the opinion of the principal investigators that would compromise patient safety.
  8. A documented history of sensitivity to modafinil.
  9. Current Modafinil use for daytime somnolence associated with obstructive sleep apnea.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboAdministered Placebo day of surgery immediately prior to general anesthesia and surgery
InterventionModafinilAdministered Modafinil 200mg day of surgery prior to general anesthesia and surgery
Primary Outcome Measures
NameTimeMethod
Length of Time From Extubation to Discharge From Postanesthesia Recovery Unit24 hours

Length of time of above compared between groups

Secondary Outcome Measures
NameTimeMethod
Postanesthesia Quality Recovery Scale Scorebaseline and 6 hours after surgery

Postanesthesia quality recovery scale (PQRS). Component and aggregate scoring on the scale. Measures physiology, nociceptive, emotional activities of daily living cognitive and overall patient perspective. The scale is dimensionless and the aggregate of all individually tested dimensions is scaled from 17-65. A higher value implies improved postanesthesia recovery. Mean difference was assessed in each patient and aggregated thus patients with no difference between pre- and post-operative scores were zeroed (received a zero score if the difference was zero). A negative value was associated with worse outcome.

Trial Locations

Locations (1)

Penn State Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath